Table 1.
Baseline characteristics of the study populations of the two treatment groups
| Variables at baseline | Patients on EFV-based regimen (n = 104) | Patients on NVP-based regimen (n = 64) | p-Value |
|---|---|---|---|
| Age (years) | 35 (6.9) | 38 (1.7) | 0.06 |
| Weight (kg) | 41.9 (7.9) | 43 (7.7) | 0.89 |
| Male gender | 81 (78%) | 51 (80%) | 0.78 |
| Alcohol consumption (often) | 43 (41%) | 31 (48%) | 0.14 |
| CD4 count (cells/mm3) | 90 (53–130) | 75 (34–130) | 0.14 |
| Viral load (copies/ml) | 259 000 (81 200–531 000) | 203 000 (87 900–370 000) | 0.79 |
| AST (U/l) | 43 (29–65) | 47 (29–52) | 0.93 |
| ALT (U/l) | 26 (16–42) | 31 (19–41) | 0.94 |
| SAP (U/l) | 127 (91–232) | 211 (74–260) | 0.78 |
| Serum bilirubin (mg/dl) | 0.4 (0.3–0.5) | 0.4 (0.3–0.5) | 0.26 |
EFV, efavirenz; NVP, nevirapine; AST, aspartate aminotransferase; ALT, alanine aminotransferase; SAP, serum alkaline phosphatase; SD, standard deviation; IQR, interquartile range.
a
Results are mean (SD), n (%), or median (IQR). Comparison between groups: t-test for means, and Wilcoxon signed rank test for medians.